Phase 2 N=169 A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Alopecia
Primary: Change From Baseline in Target Area Hair Count (TAHC) at Week 24 — 6.7; 7.1 terminal hairs/cm^2 — p=0.9239
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 LMB-2 to Treat Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Phase 2 N=113 A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Percent Change From Baseline in Mixed-meal Test (MMT) Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours to the End of Treatment (EOT) (Cohort 4)…
Phase 2 N=34 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mucositis · Oral Complications · Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Primary: Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC) — 40.9; 27.2 score on a scale — p=0.1232
Phase 2 N=222 Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Who Achieved Disease Activity Score for 28 Different Joints With C-reactive Protein Value (DAS28{CRP}) Remission (DAS28 <2.6) at Week 24 — 3…
Phase 2 N=53 6-week Safety and PD Study in Adults With NAFLD
Non-alcoholic Fatty Liver Disease
Primary: Percent Change From Baseline in Whole Liver Fat at Week 6 — -7.97; 2.84; -25.43 Percent Change — p=0.1654
Phase 2 N=26 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
Desmoplastic/Nodular Medulloblastoma · Medulloblastoma · Medulloblastoma With Extensive Nodularity
Primary: Progression-free Survival (PFS) — 52.0 percent probability
Phase 2 N=154 A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: Progression-free Survival (PFS) in Participants With Hormone Refractory Prostate Cancer (HRPC) Administered LY2181308 Sodium Plus Docetaxel Compared to Docetaxel Alone…
Phase 2 N=101 A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR) — 44.2; 57.1 Percentage of Participants
Phase 2 N=75 A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Colorectal Cancer
Primary: Percent of Patients With Disease Control — 18 Participants
Phase 2 N=341 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Phase 2 N=124 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score. — 7; 12 Participants — p=0.106
Phase 2 N=33 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
Psoriasis
Primary: The Mean Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI). — -25.08; -12.63 percent change — p=0.2205
Phase 2 N=690 Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
Pneumococcal Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 74.9; 72.3; 67.4 Percentage of Participants
Phase 2 N=90 Pain Management in Children and Young Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Participants With Successful Pain Interventions by Arm Between Presentation and 3 Hours Post Administration of Study Drug — 13; 17; 27; 25 Participants — p=0.227